Porous nanocarriers for the monitoring and treatment of bladder cancer
AssigneeNanomedtrix, LLC
InventorsJoe G. Assouline, Sean K. Sweeney
Life of this patent
Estimating the term…
Abstract
Mesoporous silica nanoparticles (MSNs) that may be useful as ultrasound contrast agents for detecting and treating bladder cancer are described herein. The MSNs include a lanthanide, a fluorophore, and an agent detectable by ultrasound.
Claims15
A composition for bladder tumor monitoring and for controlled delivery of bioactive materials comprising:
- mesoporous silica nanoparticles (MSNs), said MSNs being covalently functionalized with at least one material selected from the group consisting of a lanthanide, a fluorophore and, an agent detectable by ultrasound, whereby the MSNs are capped with gelatin or a synthetic phospholipid bilayer, and further providing that the material is covalently linked with a bladder cancer cell specific Cyc6 peptide.
A composition for delivering a therapeutic composition to bladder cancer cells in a mammal comprising:
- mesoporous silica nanoparticles (MSNs), said MSNs being loaded with one or more bioactive agents, said MSNs further being covalently linked with a bladder cancer cell specific Cyc6 peptide, whereby the MSNs are capped with gelatin or a synthetic phospholipid bilayer, said gelatin or synthetic phospholipid bilayer being crosslinked with glutaraldehyde.
A method for sequential imaging and/or imaging diagnostic or therapeutic cells in a mammal, comprising:
- a) introducing to a mammal a composition comprising mesoporous silica nanoparticles (MSNs), said MSNs being covalently functionalized with at least one material selected from the group consisting of a lanthanide, a fluorophore and, an agent detectable by ultrasound, whereby the MSNs are capped with gelatin or a synthetic phospholipid bilayer;
- and further providing that the MSNs are covalently linked with a bladder cancer cell specific Cyc6 peptide (Cyc6);
- and
- b) detecting the composition in the mammal.
A method for delivering a therapeutic composition to bladder cancer cells in a mammal comprising:
- a) loading mesoporous silica nanoparticles (MSNs) with a bioactive agent to form bioactive-loaded MSNs, said MSNs being covalently linked with a bladder cancer cell specific Cyc6 peptide (Cyc6);
- b) capping the bioactive-loaded MSNs with gelatin or a synthetic phospholipid bilayer to form capped MSNs;
- and
- d) administering the capped MSNs to the mammal.
Dependencies are inferred from the claim text.